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Besides being the main neurotransmitter in the parasympathetic nervous system, acetylcholine (ACh) can act as a signaling
molecule in nonneuronal tissues. For this reason, ACh and the enzymes that synthesize and degrade it (choline acetyltransferase
and acetylcholinesterase) as well as muscarinic (mAChRs) and nicotinic receptors conform the non-neuronal cholinergic system
(nNCS). It has been reported that nNCS regulates basal cellular functions including survival, proliferation, adhesion, andmigration.
Moreover, nNCS is broadly expressed in tumors and in different components of the immune system. In this review, we summarize
the role of nNCS in tumors and in different immune cell types focusing on the expression and function ofmAChRs in breast tumors
and dendritic cells (DCs) and discussing the role of DCs in breast cancer.
1. The Nonneuronal Cholinergic System
Organic compoundswere formed at the very beginning of the
earth, and acetylation of molecules is one of the most com-
mon reactions in nature. Because of this, it could be probable
that acetylcholine (ACh) exists since the prebiotic period.
This can be proved by the fact that ACh is present in bacteria,
blue-green algae, yeast, fungi, protozoa, and primitive plants
[1]. In addition to its presence in neurons, ACh is expressed
in pro- and eukaryotic nonneuronal cells. Thus, ACh works
as a signaling molecule in nonneuronal cells and tissues,
before its neuronal function spans. For these reasons,Wessler
et al. [2] have introduced the term “nonneuronal ACh” and
“nonneuronal cholinergic system” (nNCS) to indicate the
presence of ACh in cells independent of neurons. In turn,
Grando [3] introduced the term “universal cytotransmitter”,
which denotes the involvement of ACh in the regulation of
basic and frequently nervous-independent cell functions like
proliferation, differentiation, organization of the cytoskele-
ton, locomotion, secretion, ciliary activity, and local release of
mediators (i.e., nitric oxide and proinflammatory cytokines).
In addition, ACh is themain neurotransmitter in the neu-
ronal cholinergic system. The latter is conformed by central
and peripheral neurons. ACh is synthesized by preganglionic
fibers of the sympathetic and parasympathetic autonomic
nervous system and by postganglionic parasympathetic fi-
bers. The organization of a cholinergic neuron and synapse
is well known. In cholinergic neurons the synthesis of ACh
occurs within the nerve terminal via choline acetyltransferase
(ChAT) enzyme. ACh is accumulated in vesicles and is re-
leased by exocytosis to allow a highly effective neurotrans-
mission. The presence of nicotinic acetylcholine receptors
(nAChRs) or muscarinic acetylcholine receptors (mAChRs)
and high acetylcholinesterase (AChE) activity very close to
the synapse are needed for the rapid and short lasting action
of ACh as neurotransmitter [4]. Meanwhile, in the nNCS,
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ACh liberation occurs just after its synthesis, without being
stored in vesicles. Previous studies performed in placenta
indicate that the release of ACh in nonneuronal cells is
mediated by the family of organic cation transporters (OCT)
[5]. Three isoforms of OCT have been described: OCT1,
OCT2, and OCT3, and they are differentially expressed in
tissues and organs (i.e., OCT1 and OCT3 are expressed in
placenta and human epithelia). ACh actions are slow and
continuous in nNCS and AChE activity is lower than in
neuronal cholinergic system [6].
In summary, overwhelming evidence indicates that cells
outside the neuronal system synthesize, contain, and release
ACh. This property has been identified not only for the
abundantmajority of human cells but also in othermammals,
lower invertebrates, protozoa, plants, fungi, blue-green algae,
and even bacteria [4].
2. mAChRs and nAChRs Signal
Transduction Pathways
mAChRs belong to the family ofG-protein coupled receptors.
Five different subtypes have been genetically identified: M
1
–
M
5
[7]. The coupling of mAChRs to their cellular effec-
tor systems is mediated via heterotrimeric G-proteins that
are composed by one 𝛼-, 𝛽-, and 𝛾-subunit each and are
classified virtue to their 𝛼-subunit in four families: G𝛼s,
G𝛼i/o, G𝛼q, and G𝛼12 [8]. Receptor activation results in the
dissociation of the heterotrimeric G-protein into its 𝛼-and
𝛽/𝛾-subunits, and the latter subunits are tightly bound and
display one functional unity. Both the 𝛼-subunit and the 𝛽/𝛾-
subunit are involved in the transduction ofmuscarinic signals
(Figure 1). Thus, M
1
, M
3
, and M
5
receptors couple preferen-
tially to Gq proteins, whereas M
2
and M
4
subtypes interact
with the Gi/o family of proteins. One important target
activated by Gq represents phospholipase C mediating the
hydrolysis of phosphatidylinositol 4,5-bisphosphate to gener-
ate inositol 1,4,5-triphosphate (IP
3
) and diacylglycerol. Gi/o
proteins inhibit adenylyl cyclase activity, as well as prolong
potassium channel, nonselective cation channel and transient
receptor potential channels opening [9–11]. mAChRs have
also been shown to regulate a diverse array of signaling inter-
mediates that are not considered as classical (Figure 1). Thus,
both G𝛼i/o- and G𝛼q/11-coupled subfamily members exert
cytoskeletal effects through activation of the small GTPase
Rho and downstream effectors include phosphoinositide-3
kinases, nonreceptor tyrosine kinases, andmitogen-activated
protein kinases (MAPKs) [12].
nAChRs are a family of ligand-gated, pentameric ion
channels. The main function of this receptor family is to
transmit ACh signals at neuromuscular junctions and in
the central and peripheral nervous systems. In humans, 16
different nAChRs subunits (𝛼1–7, 𝛼9-10, 𝛽1–4, 𝛿, 𝜀, and 𝛾)
have been identified [13]. These subunits have the potential
to form a large number of homo- and heteropentameric
receptors with distinct properties and functions. Among
the 16 subunits, only the 𝛼1, 𝛼7, and 𝛼9 subunits bind an
antagonist derived from snake venom, 𝛼-bungarotoxin. Most
neuronal nAChR channels, like muscle nAChR channels, are
cation specific but do not distinguish readily among different
cations. In particular, neuronal nAChRs associated channels
allow Na+, K+, and Ca2+ transfer [13].
3. Expression and Function of
Cholinergic Receptors in Normal and
Transformed Tissues and Cells
The diversity of signaling pathways mediated by ACh effects
explains the plethora of cholinergic effects in different types
of nonneuronal cells and provides a basis for understanding
the biology of normal and malignant cells. Normal signaling
along the ACh axis is vital for growth and differentiation
of human epithelial cells. The biological effects of ACh in
nonneuronal cells are finely tuned to the regulation of each
phase of the cell cycle via the intracellular signaling pathways
coupled by each ACh receptor subtype. Each biological effect
of ACh in the epithelium is determined by a unique com-
bination of cholinergic receptors [14]. The expression of the
muscarinic receptors M
1
, M
2
, andM
3
have been described in
airways and lung tissues ofmostmammals including humans.
M
1
receptors appear to be expressed particularly in peripheral
lung tissue and alveolar wall but could not be detected in
larger airways [15]. nAChRs have been also identified in the
lung and airway epithelial cells. At present, clear evidence
exits indicating that the activation of nNCS is involved in the
control of epithelial cell adhesion, in cell-cell interactions and
proliferation, and, thus, in the regulation of epithelial layer
integrity, as well as in the interaction between airways and
immune cells [14].
In addition to their physiological functions,mAChRs and
nAChRs have been also implicated in malignant processes in
airways. The binding of endogenous ACh to both nAChRs
and mAChRs stimulates the growth of both small cell and
nonsmall cell lung carcinomas. The analysis of 28 squamous
cell lung carcinomas showed increased levels of both 𝛼5 and
𝛽3 nAChRs mRNA and ACh which were associated with
increased levels of ChAT and decreased amounts of AChE
mRNAs. Thus, cholinergic signaling is broadly increased in
this type of tumor due to the high levels of expression of both
receptors and ligands [16].
The cholinergic circuitry of the enteric system is extensive
and mediates motility (muscular) and secretory (mucosal)
reflexes, in addition to intrinsic sensory and vascular reflexes.
The capacity of ACh to mediate multiple physiologically
significant intestinal reflexes is largely due to the presence
of multiple sites of neuronal and nonneuronal release and
reception within the intestine. The five subtypes of mAChRs
have been identified in epithelia, muscle, and nerves, and
M
3
receptor subtype is the major regulator of motility and
secretion in these tissues.This receptor has been also involved
in the regulation of colon cancer cells proliferation through
the transactivation of the EGFR-ERK pathways [17].
Kurzen et al. [18] demonstrated an essential role for ACh
and its receptors in epidermal physiology using organotypic
cocultures. The blocking of nAChRs and mAChRs with
mecamylamine and atropine, respectively, for 7–14 days
results in the complete inhibition of epidermal differentiation
andproliferation. nAChRs inhibition led to a less pronounced
delay in epidermal differentiation and proliferation than that
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Figure 1: Subtypes of cholinergic receptors, transduction, and effects. Muscarinic acetylcholine receptors (mAChR); nicotinic acetylcholine
receptors (nAChR); acetylcholine (ACh); phospholipase C (PLC); inositol triphosphate (IP
3
); diacylglycerol (DAG); protein kinase C (PKC);
adenylyl cyclase (AC); cyclic adenosinemonophosphate (cAMP); inositol triphosphate kinase (IP
3
K); Janus kinase (JNK); mitogen-activated
protein kinase (MAPK); extracellular kinase (ERK); nuclear transcription factor-𝜅B (NF-𝜅B); inducible nitric oxide synthase (iNOS); tumor
necrosis factor alpha (TNF-𝛼); interleukin (IL); high mobility group box 1 (HMGB1).
obtained by blocking mAChRs with atropine, which was
evidenced by reduced epithelial thickness and expression
of terminal differentiation markers. In contrast, stimulation
of nAChRs and mAChRs with cholinergic drugs results
in a significant epithelium thickening accompanied by an
improved epithelial maturation. Merkel cell carcinoma is
a highly aggressive neuroendocrine carcinoma of the skin.
More than one-third of the patients with this carcinoma will
die, making it twice as lethal as malignant melanoma. Other
authors have analyzed fifteen cases of primary nonmetastatic
cutaneousMerkel cell carcinoma and detected the expression
of 𝛽2 nAChR and mAChR subtypes 3 and 5 which could be
linked to malignant cell proliferation and migration [19].
nAChRs and mAChRs are well-known modulators of
brain functions. Previous works have indicated that mAChRs
are expressed in primary cultures of oligodendrocytes and
that their activation promotes cell proliferation via MAPKs.
It has been also demonstrated that mAChRs activation
increases cell survival and differentiation [20, 21]. Other
authors detected the expression of M
3
receptors in SH-
SY5Y human neuroblastoma cells. The stimulation of these
receptors leads to an increase in intracellular calcium levels
and IP
3
formation in these cells, both events are known to
trigger cell proliferation [22].
3.1. mAChRs Expression and Function in Breast Cancer. Un-
like other tissues, normal breast tissues do not express cholin-
ergic receptors. In our laboratory, we have confirmed that
normalmurinemammary cellsNMuMG, aswell asMCF-10A
cells, derived from normal human breast, show no-positive
immunostaining by Western blot or by specific radio-ligand
binding for any subtype of mAChRs [23–25]. In addition,
we have also observed, by using immunoblotting techniques,
thatmAChRswere absent in homogenates of surgical samples
obtained from normal human mammary tissue [25]. On
the contrary, we found that mAChRs are constitutively
expressed in three different cell lines LM2, LM3, and LMM3
derived frommurinemammary adenocarcinomas that spon-
taneously arose in BALB/c mice. Stimulation of these func-
tional receptors potentiates different stages of tumorigenesis,
such as cell proliferation, migration, angiogenesis, and tumor
growth in vivo [26–28]. We observed that LMM3 cells, which
were obtained froma lungmetastasis ofM3 tumor, upregulate
mAChRs expression up to 50-fold in comparison with LM3
cells, suggesting that mAChRs couldmodulate the metastatic
ability of tumor cells [27]. As it was shown in other tumor
cell types (i.e., lung, colon, or melanoma), LMM3 tumor
cells exhibit a major expression of M
3
subtype, which mainly
mediates the proliferative action induced by the choliner-
gic agonist carbachol. Similarly, MCF-7 cells, derived from
an estrogen-dependent human mammary adenocarcinoma,
express the M
3
and M
4
subtypes of mAChRs (Figure 2) [29].
Stimulation of mAChRs with carbachol potentiates different
steps of tumor progression. Particularly, we have observed
that this agonist stimulates tumor proliferation. This action
involves the participation of the M
3
receptor signaling path-
way which couples phospholipase C/nitric oxide synthase,
protein kinase C effector enzymes. Carbachol also triggers
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Figure 2: Expression and function ofmuscarinic acetylcholine receptors (mAChR) in breast tumor cells. Carbachol (Carb) stimulatesmAChR
and via Gq/11 protein increases phospholipase C (PLC) activity. This enzyme hydrolyzes phosphoinositides producing myoinositol 1,4,5-
trisphosphate (IP
3
) and increases intracellular calcium levels which in turn activates nitric oxide synthase (NOS) that produces nitric oxide
(NO). mAChRs also couple to Gi protein and inhibit the activation of adenilyl cyclase (AC) reducing cAMP formation. The agonist also
increases synthesis and liberation of vascular endothelial growth factor-A (VEGF-A) and metalloproteinase-9 expression and activity in
tumor cell supernatants.
nitric oxide synthesis and vascular endothelial growth factor-
A (VEGF-A) expression increasing blood vessels formation
induced by mammary tumor cells in nude mice [29, 30].
Recently, we have demonstrated that stimulation of mAChRs
in MCF-7 cells increases tumor invasion by upregulating cell
migration andmetalloproteinase-9 expression and activity in
cell supernatants (Figure 2) [31].
4. nNCS in Immune Cells
ACh is synthesized by mononuclear leukocytes (MNL), bone
marrow-derived dendritic cells (BMDCs),macrophages, skin
mast cells, and human leukemic T-cell lines [32, 33]. It
has been described that lymphocytes produce and secrete
ACh depending on its differentiation and/or activation status
[34]. Among T-cell subsets, CD4+ cells have a higher ability
to synthesize ACh than CD8+ cells [35]. The synthesis of
ACh in T cells is enhanced by activation of the T cell
receptor (TCR)/CD3-mediated pathways, suggesting that the
interaction of T cells with DCs during antigen presenta-
tion stimulates nonneuronal cholinergic activity. Besides the
presence of ChAT activity, mRNA, and enzyme protein has
also been detected in immune cells, such as CD8+ and
CD4+ T cells, DCs, peripheral blood MNL, granulocytes,
and mast cells [36–40]. Fujii et al. [35] demonstrated that
the stimulation of T cells with phytohemagglutinin and
dibutyryl cAMP enhances the synthesis and release of ACh
and upregulates ChAT mRNA expression, suggesting that
both drugs increase ChAT activity through the induction
of ChAT gene transcription. The concentration of ACh is
determined by the rates of release and diffusion across the
plasma membrane and also by the hydrolysis mediated by
AChE; thus, this concentration should be much higher at the
receptor sites than in the bulk plasma or conditioned media
[33].
Additionally, the expression of the components of nNCS
including choline high affinity transporter 1, ChAT, and
vesicular acetylcholine transporter was detected in cells of the
monocyte-macrophage lineage [41].
Most human MNL, T and B cells, thymocytes, human
leukemic cell lines, and animal immune cells express dif-
ferent subtypes of cholinergic receptors [38]. All subtypes
of mAChRs have been detected in cells of the monocyte-
macrophage lineage [41]. In freshly isolated CD4+ and CD8+
T cells, mRNAs encoding 𝛼5, 𝛼9, 𝛼10, 𝛽1, 𝛽2, and 𝛽4 nicotinic
subunits and M
1
, M
3
, M
4
, and M
5
receptors were detected,
while the𝛼2 subunit is present only inCD8+ T cells. However,
the level of expression for each subtype of receptor appears to
vary with immune status [42].
Regarding DCs, it was observed that human monocyte-
derived DCs express only the 𝛼7 subunit of nAChR and
murine bonemarrow-derived DCs express different nAChRs
[43]. On the other hand, it has been described that DCs
isolated from surgically removed nasal mucosa express the
M
3
subtype [44]. Our results indicate that humanmonocyte-
derived DCs express M
3
, M
4
, and M
5
receptors as well as
ChAT and AChE in both immature and mature DCs [40].
5. Role of nNCS in the Modulation of
the Immune System
ACh is able to modulate different functions in immune cells,
such as the activation of CD8+ T cells [37, 45, 46], the release
of chemotactic factors from bovine alveolar macrophages
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trophic for neutrophils, monocytes, and eosinophils [47],
and the release of leukotriene (LT) B4 from human and
bovine alveolar macrophages, at less in part by M
3
receptor
activation [48]. It has been shown that stimulation of the
nAChRs in peritoneal macrophages increased phagocytosis
[49] whereas mAChRs activation promotes metabolic and
phagocytic activity in neutrophils [50].
The equilibrium between pro- and anti-inflammatory
cytokines and their sequential release may be one of the
key factors that accounts for the severity of inflammatory
responses. The presence of ACh can mediate opposite func-
tions during inflammatory processes. Chronic stimulation of
nAChRs suppresses the immune and inflammatory response
causing T-cell anergy and decreased leukocyte migration.
Similarly, the addition of ACh in the presence of AChE
inhibitors in LPS-stimulated macrophages reduces the pro-
duction of TNF-𝛼, IL-1𝛽, IL-6, and IL-18 through nAChR
activation [51, 52]. This anti-inflammatory effect is mediated,
at least in part, by 𝛼7 nAChR given that is abolished in 𝛼7 KO
mice [53, 54]. Further reports propose that this effect could
be also mediated by 𝛼4 and 𝛽2 subunits in murine alveolar
macrophages that do not express the 𝛼7 subunit [55].
On the other hand, acute activation of nAChRs in several
cell types stimulates immune and inflammatory responses
by a mechanism that includes the increase of intracellular
calcium levels. Although activation of nAChRs on T cells
stimulates protein tyrosine kinase activities and raises intra-
cellular Ca2+ concentration no electrophysiological evidence
supports the presence of nicotine-sensitive, ligand-gated
cation channels on these cells. In contrast, 𝛼7-nAChR sub-
units can interact with the TCR/CD3 and raise intracellular
Ca2+ through the TCR-associated signaling pathway. Some
authors have suggested that this interaction could act as a
costimulatory signal to trigger immune receptor activation
[56].
Previous studies have shown that, in murine splenic T
cells, nicotinergic stimulation upregulates interferon-𝛾 (IFN-
𝛾) liberation and downregulates interleukin IL-17 secretion,
whereas muscarinic activation enhances IL-10 and IL-17
and inhibits INF-𝛾 secretion. Taken together, these results
demonstrate the plasticity of the T-cell cholinergic system
[42].
Stimulation of B cells with Staphylococcus aureus upreg-
ulates M
5
receptor expression and ACh synthesis suggesting
that the immunological activation of lymphocytes facilitates
cholinergic signaling [57].
The use of knockout mice has allowed a better character-
ization of cholinergic receptors and their role in the mod-
ulation of the immune response. Fujii et al. [58] described
that M
1
/M
5
KO mice, immunized with ovoalbumin, have
lower serum concentrations of anti-OVA-specific IgG
1
than
wild-type mice. In addition, activated MNL obtained from
these mice have lower AChE mRNA expression and exhibit
a reduced secretion of proinflammatory cytokines (TNF-𝛼
and IL-6). These results suggest that M
1
and/or M
5
receptors
are involved in the regulation of pro-inflammatory cytokines
production, leading to the modulation of antibody synthesis.
Other pieces of evidence indicate that ACh not only is
able tomodulate inflammatory processes but also participates
in the development of several diseases. Cystic fibrosis is
associated with enhanced infections and it has been reported
that the content of ACh is significantly reduced in the airways
and peripheral leucocytes in fibrotic patients revealing a
dysfunction in nNCS in this disease [59]. ACh limits the
migration of peripheral granulocytes. Wessler et al. [60] have
described that this effect is impaired in cystic fibrosis most
likely because of a reduced endogenous cholinergic tone.
Myasthenia gravis is a B-cell-mediated, T-cell-dependent,
antibody-mediated autoimmune disorder in which nAChRs
at the neuromuscular junction are the major autoantigens. In
this illness, the proliferation of cholinergic receptors-reactive
lymphocytes is increased and anticholinergic receptor IgG
and inflammatory cytokine levels (IFN-𝛾, TNF-𝛼, IL-6, and
IL-17) are enhanced [61, 62].
6. Cholinergic Modulation of DCs Function
DCs are the most potent professional antigen presenting
cells which can uptake, process, and present different types
of antigens, including tumor antigens [63, 64], to antigen-
specific na¨ıve T cells. DCs, which originated from bone
marrow hematopoietic progenitor cells, can be found in
immature or semimature state in different nonlymphoid
tissues and organs. In this state DCs act as sentinels of
the immune system by efficiently capturing and processing
foreign antigens. In the presence of a “danger signal” (such
as infection or inflammation), DCs shift from an antigen-
capturing mode to a T-cell sensitizing mode, a phenomenon
called “maturation” which is usually associated with their
migration to secondary lymphoid tissues where they provide
signals 1–3 to T lymphocytes [63].
It has been reported that activation of the nAChRs
modulates the function of DCs. Human monocyte-derived
DCs express the 𝛼7 nAChR while murine bone marrow-
derived DCs express different nAChRs [43]. Nicotine may
have effects on DCs activity by regulating their local cytokine
environment and consequently modify indirectly their func-
tion in primary specific immune responses [50]. Moreover,
supporting an anti-inflammatory function of the nAChRs
in human DCs, it has been shown that stimulation of the
nAChRs reduces phagocytosis and endocytosis activities
in human DC and decreases the levels of inflammatory
cytokines production (IL-1𝛽, TNF-𝛼, and IL-12) triggered
by LPS, which are crucial for the recruitment of T cells in
response to inflammatory stimulation [49, 65]. Additionally,
some authors have suggested that the impairment of DCs
function by nicotine may also be related to the increased
occurrence of infections in smokers [60].
Interestingly, other studies have shown that nicotine, act-
ing on resting humanDCs, stimulates not only the expression
of costimulatory molecules but also the production of IL-
12 and their ability to stimulate T-cell proliferation [43, 66,
67]. These results suggest that nicotinic stimulation might
be able to exert different effects on DCs depending on their
maturation status.
Similarly, Salamone et al. [40] have analyzed the ability of
ACh to modulate the functional profile of human monocyte-
derived DCs and found induced opposite effects on resting
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Figure 3: Cholinergic actions on human dendritic cells (DCs). DCs express all the components of the nonneuronal cholinergic system:
muscarinic acetylcholine receptors (mAChR), acetylcholine transferase (AChT), and acetylcholinesterase (AChE).The activation of mAChR
with carbachol (Carb) in immature DCs (iDCs) upregulates deexpression of HLA-DR and the liberation of tumor necrosis factor (TNF) and
interleukin-8 (IL-8) and stimulates demix lymphocyte reaction (MLR), while the activation of mAChR with Carb in mature DCs (mDCs)
downregulates HLA-DR, TNF, and IL-12 and reduces MLR.
and LPS-triggered DCs indicating that the ability of the
cholinergic system to modulate the functional profile of DCs
is strongly dependent on their activation status. Besides,
muscarinic stimulation increases the expression of HLA-
DR and CD86 and the production of TNF-𝛼 and IL-8 in
immature DCs. The increment in HLA-DR expression by
cholinergic activation is dependent on TNF-𝛼 production in
an autocrine and/or paracrine manner. On the other hand,
the addition of the muscarinic agonist carbachol to LPS-
stimulated DCs reduced the expression of HLA-DR and the
production of TNF-𝛼 and IL-12 (Figure 3).
Interestingly, Liu et al. [44] have investigated the role of
the mAChRs in nasal mucosal immune cells of patients with
polyposis, which is associated with inflammatory disorders
in the lower airways. They found that microbial products
upregulate the expression of M
3
receptor in nasal mucosal
immune cells and as a consequence the cholinergic stimu-
lation of DCs improves the inflammatory activity of these
cells by increasing the production of OX40L. In addition,
DCs modulate the production of TNF-𝛼 and IL-4 in nasal
mucosa by CD4+ T cells that may further contribute to the
pathogenesis of polyposis.
7. Functional Significance of
Tumor-DCs Interactions
Activation and maturation of DCs depend on the local
microenvironment and can be blocked or polarized by spe-
cific factors or their combinations resulting in the formation
of DCs subsets with tolerogenic and immunosuppressive
activities [68, 69]. The lineage relationship between these
different subsets, their responsiveness to different pathogens,
and the mechanisms by which they influence the immune
response are areas of intense investigation and have been
reviewed extensively [70, 71]. The tumor microenvironment
is capable of inactivating various components of the immune
system responsible for tumor clearance. In particular, the
effect of the tumor microenvironment on DCs does not
only render these immune cells unable to induce specific
immune responses but also turns them into promoters of
tumor growth.
7.1. DCs as Inducers of Tumor Immunity. According to the
cancer immunosurveillance and immunoediting paradigm
the immune system has the ability to detect and remove
emerging malignant cells preventing their uncontrolled pro-
liferation [72–75]. At the beginning of every cellular immune
reaction against cancer, tumor antigens have to be presented
to T cells in order to activate them and drive them into
clonal expansion. This task is done by antigen presenting
cells, the most potent of which are the DCs. Tumor-specific
T-cell activation begins in the primary tumor when DCs
encounter antigens in the formof apoptotic or necrotic tumor
cells. Then, DCs engulf dying tumor cells and process their
antigens into peptides that are presented in the context of
MHCclass I and class IImolecules [76, 77]. In addition, T-cell
activation requires engagement of costimulatory receptors
on the T-cell, adequate types and concentrations of T-
cell-activating cytokines and T-cell-attracting chemokines,
and maintenance of the activation signal over a sufficient
period of time. DCs can accurately control the outcome of
immune activation by means of differential surface receptor
expression, and T cells in turn signal back to modulate
the function of DCs. Apart from generating an antitumor
immune response, DCs also play an active role in the erad-
ication of tumors themselves, since DCs have been shown to
kill tumor cells via expression of death receptor ligands [78],
and DCs activated by pro-inflammatory cytokines or LPS
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can directly inhibit the growth of tumor cell lines [79].
Thus, DC has the potential ability of developing tumor-
specific immune response. However, this does not occur in
most types of cancer or in animal models of spontaneously
arising tumors. Instead of being eliminated by the immune
response, tumors progress,metastasize, and, ultimately, result
in death of the host. Much clear evidence has demonstrated
deficient functional activity of DCs in cancer [77–80]. The
main conclusion from these studies was that DCs in tumor-
bearing hosts could not adequately stimulate an immune
response, and this could contribute to tumor evasion of
immune recognition. Now, it is increasingly clear that the
DCs defects in cancer are systemic and are not localized to
tumor tissues.
7.2. DCs Infiltrating Breast Tumors. Innate immune cells
(DCs, natural killer cells, granulocytes, myeloid derived
suppressor cells, macrophages, and monocytes) are present
in the normal mammary gland and play an important role
in the function of the tissue actively participating in mam-
mary gland development and remodelling [80–82]. They are
present in even higher numbers in neoplastic tissues, such as
breast tumors. This increased infiltration of innate immune
cells in the tumor tissue might be seen as an attempt of
the body to combat the disease. However, high infiltration
correlates with poor prognosis for patients [83]. Thus, in line
with these observations innate immune cells in vivo primarily
exert activities that support tumor growth, for example, by
stimulating angiogenesis [84]. In contrast, in vitro, innate
immune cells possess effective antitumor activities, such as
direct killing of cancer cells [85].
Observations from many clinical studies have noted
infiltration of tumors with DCs [86].The clinical significance
of tumor-infiltrating DCs (TIDCs) has been reported in a
large variety of humanmalignancies. In general, the presence
of DCs in tumors has been associated with better prognosis,
reduced tumor recurrence, and fewer metastases [87]. The
S100 protein was the first marker introduced to identify
DCs. TIDCs are heterogeneous in regard to maturation,
differentiation, and state of activation and are controlled
and regulated by a variety of microenvironmental signals,
including cytokines and other surface molecules expressed
on neighbouring cells [87]. The conceptual progress in the
field of DCs physiology and the availability of novel markers
differentiating DC subsets has allowed us to reevaluate DCs
infiltration in breast carcinoma tissue. The use of specific
markers has made it possible to identify the maturation state
of TIDCs. Bell et al. have demonstrated the unique com-
partmentalization of immature and mature DCs infiltrating
the breast carcinoma tissue [77]. These authors found that
immature CD1a+ DCs, mostly of the Langerhans cell type
(Langerin+), are retained in more than 90% of breast cancers
within the tumor bed whereas mature DCs, CD83+ DC-
Lamp+, recorded in 60% of the examined samples, are con-
fined to peritumoral areas. The high numbers of immature
DCs found in the tumor may be best explained by high levels
of macrophage inflammatory protein 3𝛼 (MIP-3𝛼/CCL20)
expressed by virtually all tumor cells. In some cases, T cells
cluster around mature DCs, resembling the DC and T-cell
clusters of secondary lymphoid organs characteristic of ongo-
ing immune reactions [87]. In a complementary study, Iwa-
moto et al. [88] have established the prognostic significance of
tumor infiltration by immature and mature DCs by revealing
that the presence of CD83+ TIDCs was inversely correlated
with lymph node metastasis. These results were confirmed
by other studies in which higher numbers of CD83+ DCs
were found in tumor-free sentinel lymph node (SLNs) than
in tumor-containing SLNs. In addition, tumor-free SLNs
contained significantly higher numbers of IL-10-expressing
cells. Both of these observations support the hypothesis that
a tumor-free SLN is immunologically competent and a site
of tumor-specific T-cell activation [89]. The mechanisms by
which tumor immunity is affected within the SLN are not
fully understood. However, it is well known that tumor cells
produce various immunosuppressive factors, including TGF-
𝛼, IL-10, and PGE2, and vascular endothelial growth factor
(VEGF) [90–92].
Studies using tissues from human breast cancer patients
have documented infiltration of plasmacytoid DCs (pDCs)
at the periphery of the tumor and at sites of metastasis
[93, 94]. pDCs are well known for their role in antiviral
immunity as they massively produce type I interferons
(IFN𝛼/𝛽/𝜔) in response to viral nucleic acids recognized by
TLR7 and TLR9. They are also involved in the pathogenesis
of autoimmune/inflammatory disorders. In addition to their
innate immunostimulatory functions, pDCs exhibit adaptive
tolerogenic properties by favouring the differentiation and
expansion of immunosuppressive FOXP3+ regulatory T cells
(Treg) [95]. The accumulation of pDCs within breast car-
cinoma lesions is associated with a poor clinical outcome.
It was demonstrated that the deleterious impact of tumor-
associated pDCs is due to their impaired capacity to produce
type I interferon, which in turn potentiates their ability to
sustain the proliferation of immunosuppressive Treg cells
[96]. Elevated levels of pDCs have been observed as breast
cancer disseminates to the bone suggesting that pDCs may
play a key role in the establishment of breast cancer osteolytic
bone metastases [97].
7.3. Circulating DCs in Breast Cancer Patients. Substantial
evidence exists showing impairment of the systemic immune
response during breast cancer progression. Several groups
have described differences in differentiation of circulating
monocytes into DCs which persisted in cancer patients as
compared with healthy donors [98, 99]. In patients with
cancer, it has been shown that rapidly growing tumors con-
tain small numbers of DCs and that those cells usually have
the phenotype of immature DCs (iDCs) [100]. iDCs cannot
induce antitumor immune responses but instead they are
able to induce T-cell tolerance or anergy. Using the classic
procedure of blood monocyte-derived DCs culture (in the
presence of IL-4 and GM-CSF), the ex vivo yield of DCs
was found to be significantly reduced in patients with cancer,
particularly in those with breast cancer [101]. The phenotype
of monocyte-derived DCs in patients with breast cancer was
found to express low levels of MHC class II as compared
with healthy patients. Moreover, whatever combination of
maturating agents was used, significantly lower expressions
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of mature DC markers (CD80 and CD86) were observed in
patients with breast cancer [98], whereas DCs isolated from
breast cancer patients demonstrate impaired phagocytosis
and a significantly reduced ability to stimulate allogeneic and
antigen-specific T-cell responses [100]. Interestingly, pDC
numbers are not affected. Several clinical studies have shown
that surgical removal of tumors can increase the number of
DCs in the peripheral blood of patients with cancer [102].
Tumor infiltrating and circulating bloodDCs fromcancer
patients are compromised in their functional activity. Even
though it is still under debate which factors are involved in
the inhibitory activity of tumor cells, ex vivo culture seems
to be able to circumvent the suppressive activity of the tumor
milieu.
7.4. The Breast Cancer Immune Microenvironment. Develop-
ment of cancer not only is determined by the tumor cells
themselves but also depends on the tumor environment [103].
The tumor stroma consists of fibroblasts, endothelial cells,
and extracellularmatrix components and a considerable frac-
tion of the inflammatory infiltrate is locatedwithin this tumor
stroma. Besides the tumor cells, tumor stroma produces a
variety of cofactors including cytokines, chemokines, growth
factors, hormones, prostaglandins, lactate, and gangliosides.
The interplay between all of these factors and cell populations
defines the tumor environment [104, 105].
Breast tumors generate a milieu in which innate immune
cells are skewed towards a type II polarization and are thus
pushed towards roles as “villains” [105]. Anti-inflammatory
cytokines, such as IL-10 andTGF-𝛽, are themain contributors
of this milieu. These factors are produced by tumor and stro-
mal cells, and they act directly on immune cells by impairing
their ability to secrete pro-inflammatory factors [106, 107].
These anti-inflammatory signals may also be secreted by
regulatory T cells, which are found in elevated numbers in
human breast tumors [108].
7.5. Tumor-Derived Factors Involved inDefectiveDCsDifferen-
tiation and Activity. As it was mentioned above, DCs defect
in cancer is systemic and this indicates that it is mediated
by soluble factors produced by tumor cells. This concept
is directly confirmed by the observation that normal DCs
differentiation and activity are restored after surgical removal
of tumors. Moreover, when DCs precursors isolated from
tumor-bearing hosts are cultured in the absence of tumor-
cell-conditioned medium, the differentiation of DCs is nor-
mal [100]. The defects of DCs differentiation and activity in
cancer are due to the combination of many different factors
which will be briefly summarized herein.
7.5.1. Vascular Endothelial Growth Factor (VEGF). This was
the first tumor-derived factor shown to inhibit DCs differ-
entiation. VEGF has an important role in the formation of
blood vessels and in haematopoiesis during embryogenesis.
VEGF plays dual roles in the tumor microenvironment by
inducing angiogenesis and inhibiting DCs function [109].
In recent years, large clinical data have supported the fact
that the expression of VEGF negatively correlates with DCs
numbers in the tumor tissue and peripheral blood of patients
with cancer [110].
7.5.2. Interleukin-10 (IL-10). Different tumor, stromal cells,
and tumor-infiltrating lymphocytes produce and release IL-
10 [111]. Anti-inflammatory cytokines, such as IL-10, act
directly on immune cells by impairing their ability to secrete
pro-inflammatory factors. IL-10 promotes the differentiation
of iDCs into tolerogenic DCs by decreasing their expression
of co-stimulatory molecules [112]. IL-10 has also been shown
to block the differentiation of monocytes into DCs, but it
promotes their maturation into macrophages [113].
7.5.3. Other Tumor Metabolites. Arachidonic acid metabo-
lites, including prostaglandins and thromboxanes, are syn-
thesized by cyclooxygenase-1 and 2 (COX-1/2). In many can-
cers, such as melanoma, colon, breast, lung, and ovarian car-
cinoma the expression of COX-2 is altered [114, 115]. Besides
the direct effect on tumor growth, apoptosis, cell to cell inter-
action, and angiogenesis, prostanoids seem to suppress host
immunity against tumors [116] with particular effects on DCs
activity [117]. Prostaglandin E
2
(PGE
2
) was also described
as an important factor for the generation of potent T-cell
stimulatory DCs. When DCs are cultured simultaneously
with a cocktail of pro-inflammatory cytokines including IL-
6, IL-1𝛽, and TNF-𝛼 in the presence of PGE
2
the mature DCs
obtained present potent T-cell stimulatory capacity [118]. Fur-
thermore, the migratory capacity of monocyte-derived DCs
seems to depend on the presence of PGE
2
and increases the
expression of CCR7, the CCL19/CCL21 receptor [119]. On the
other hand, PGE
2
upregulates indoleamine 2,3-dioxygenase
(IDO) thereby inhibiting T cell proliferation due to IDO-
induced tryptophan depletion [120] and thus inducing DCs-
mediated T-cell tolerance in the tumor microenvironment.
8. Concluding Remarks
Many aspects of breast cancer promotion and progression
are still not completely solved. The activation of mAChRs in
breast tumors promotes malignant progression and worsens
the condition of tumor bearers. In particular, the activation
of cholinergic receptors in immature DCs could favor tumor
antigen presentation through HLA-DR expression and on
the other hand could promote a pro-inflammatory status
facilitating antitumor responses that control tumor growth.
Altogether, stimulation of mAChRs in DCs should be con-
sidered as an adjuvant target in cancer therapeutics to break
DCs tolerance against tumors.
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